Brief Summary

The primary objective of the first phase of this project is to demonstrate a reduction in pain intensity of at least 50%, as assessed by a visual analog scale, after an intravenous lidocaine infusion in patients suffering from a chronic inflammatory bowel disease (IBD). The second phase aims at studying the changes in brain connectivity after an intravenous lidocaine infusion in a population of patients suffering from IBD with abdominal pain, and to compare these changes with those observed in a group of healthy volunteers.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: recruiting
Reported enrollment (type unavailable): Not reported
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
April 25, 2024
Actual (reported)

Conditions

Inflammatory Bowel disease

Outcome Measures

Primary Outcomes (1)

We hope to be able to reduce the background pain scores and decrease the frequency of hyperalgesia flare-ups, and thus reduce the psychosocial impacts associated in these patients.